Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Swerdlow SH, Webber SA, Chadburn A, Ferry JA . Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (eds). WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues 4th edn International Agency for Research on Cancer: Lyon, 2008; pp 343–350.

    Google Scholar 

  2. Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196–206.

    Article  CAS  PubMed  Google Scholar 

  3. Montserrat E . PTLD treatment: a step forward, a long way to go. Lancet Oncol 2012; 13: 120–121.

    Article  PubMed  Google Scholar 

  4. Trappe RU, Dierickx D, Reinke P, Neuhaus R, Morschhauser F, Zaucha JM et al. Interim analysis of the largest prospective trial to date in adult CD20-positive post-transplant lymphoproliferative disorder (PTLD): introducing risk-stratified sequential treatment (RSST). ASCO Meeting Abstracts 2012; 30 (Suppl): 8030.

    Google Scholar 

  5. Kim DH, Baek JH, Chae YS, Kim Y-K, Kim HJ, Park YH et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007; 21: 2227–2230.

    Article  CAS  PubMed  Google Scholar 

  6. Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab. Eur J Haematol 2008; 81: 448–453.

    Article  PubMed  Google Scholar 

  7. Song M-K, Chung J-S, Seol Y-M, Kim S-G, Shin H-J, Choi Y-J et al. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Ann Oncol 2010; 21: 140–144.

    Article  PubMed  Google Scholar 

  8. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, INM Micallef, Johnston PB et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 2011; 25: 1502–1509.

    Article  CAS  PubMed  Google Scholar 

  9. Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN . Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol 2010; 85: 896–899.

    Article  PubMed  Google Scholar 

  10. Li Z-M, Huang J-J, Xia Y, Sun J, Huang Y, Wang Y et al. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One 2012; 7: e41658.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL . Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol 2006; 97: 993–996.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to R U Trappe.

Ethics declarations

Competing interests

The German and the French PTLD Study Groups were supported by Roche, AMGEN and Chugai to conduct the PTLD-1 trial with an unrestricted grant. SC received payment for lectures, research grants and consultancy fees from Roche. GS received payment for consultancy, honoraria and/or advisory board membership from Roche and/or Genentech and is an advisory board member for Celgene, Janssen-Cilag, Genzyme, Calistoga/Gilead and Mundipharma. FM received payment for consultancy, honoraria and/or advisory board membership from Roche and/or Genentech and is an advisory board member for Celgene, Spectrum and Mundipharma. CT received honoraria from Roche. VL is on the advisory board for Janssen-Cilag and Pharmacyclics, and received travel support from Roche and Honoraria from Janssen-Cilag and Mundipharma. RUT received payment for lectures and consultancy from CSL Behring, Mundipharma and/or Roche, grant support from AMGEN, CSL Behring, Mundipharma and Roche, and travel support from AMGEN, CLS Behring and Roche. The remaining authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zimmermann, H., Choquet, S., Moore, J. et al. Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial. Leukemia 27, 2102–2105 (2013). https://doi.org/10.1038/leu.2013.110

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.110

This article is cited by

Search

Quick links